Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Whitehawk Therapeutics (WHWK) Revenue (2018 - 2025)

Whitehawk Therapeutics (WHWK) has disclosed Revenue for 7 consecutive years, with $7.1 million as the latest value for Q1 2025.

  • On a quarterly basis, Revenue rose 33.48% to $7.1 million in Q1 2025 year-over-year; TTM through Sep 2025 was $14.4 million, a 42.62% decrease, with the full-year FY2024 number at $26.0 million, up 6.69% from a year prior.
  • Revenue was $7.1 million for Q1 2025 at Whitehawk Therapeutics, down from $7.2 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $14.0 million in Q4 2021 to a low of -$227000.0 in Q2 2021.
  • A 5-year average of $5.4 million and a median of $5.9 million in 2023 define the central range for Revenue.
  • Peak YoY movement for Revenue: plummeted 101.51% in 2021, then soared 1822.5% in 2022.
  • Whitehawk Therapeutics' Revenue stood at $14.0 million in 2021, then tumbled by 62.66% to $5.2 million in 2022, then rose by 21.03% to $6.3 million in 2023, then increased by 14.43% to $7.2 million in 2024, then fell by 1.3% to $7.1 million in 2025.
  • Per Business Quant, the three most recent readings for WHWK's Revenue are $7.1 million (Q1 2025), $7.2 million (Q4 2024), and $7.2 million (Q3 2024).